Alba Fiorentino, Full Professor of Radiation Oncology and Head of the Radiation Oncology Residency Program at LUM University of Medicine, Chief of Diagnostic and Therapeutic Department, Chief of Radiation Oncology at MIULLI.art H-index 32, shared a post on LinkedIn about recent article she and her colleagues authored:
“Here, our new publication for GBM.
Several studies on Hypo-radiotherapy in high-grade gliomas have shown promising results in terms of both effectiveness and toxicity, demonstrating a biological effective dose (BED) comparable to that of traditional RT.
Patients with IDH-wild-type GBM received either Hypo-RT (40.05–52.5 Gy/15 fractions) or S-RT (60–70 Gy/30 fractions). Volumetric modulated arc therapy was performed for all patients. Concomitant and adjuvant temozolomide were administered.
The time to progression for the S-RT and Hypo-RT groups was 13.7 and 11.1 months, respectively (p = 0.243). Regarding OS, the S-RT group had a median OS of 28.8 months compared to 17.5 months in the Hypo-RT group (p = 0.007).
This is likely due to differences in the populations, specifically, those in the S-RT were younger (only 14% were over 65 years old compared to 50% in the Hypo-RT arm), had a complete surgical resection (42% versus 19%, biopsy was performed in 19% versus 37%). However, in the hypo-arm, OS was better than that reported in other Hypo-RT trials, despite the frail and poor prognosis population (Ryan et al., a median OS of 9 months and a 2-year OS of 9% versus a median OS of 17.5 months and a 2-year OS of 43.3%, in the present analysis).
In conclusion, Hypo-RT (52.5Gy in 15fx) could potentially become the standard of care not only for elderly patients but also for those with poor prognosis.
Thanks to Fiorella Di Guglielmo, Ilaria Bonaparte, Valerio Davi and all Miulli.art.”
Title: Are conventional and hypofractionated chemoradiotherapy comparable in glioblastoma patients?
Authors: Fiorella Cristina Di Guglielmo, Ilaria Bonaparte, Valerio Davì, Pietro Guida, Maria Paola Ciliberti, Fabiana Gregucci, Alessia Surgo, Morena Caliandro, Roberta Carbonara, David Giraldi, Vincenzo Fanelli, Giammarco Surico, Maria Annunziata Gentile, Roberto Calbi, Valeria Internò, Letizia Laera, Tiziana Talienti, Francesco Signorelli, Giuseppe Lombardi, Alba Fiorentino
Read More about GBM on OncoDaily’s Special Article: “Glioblastoma: Causes, Symptoms, Diagnosis, Treatment, and Latest Advances in 2025”
